• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, August 29, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Lundquist Principal Investigator Dr. Michael Yeaman awarded $11.5 million NIAID/HHS grant for innovative research to understand and solve persistent bloodstream infections

Bioengineer by Bioengineer
August 15, 2023
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

The Lundquist Institute (TLI) at Harbor-UCLA Medical Center announced today that TLI Principal Investigator, Michael Yeaman, PhD, has been awarded a grant totaling $11.5M from the National Institute of Allergy and Infectious Diseases (NIAID), Department of Health & Human Services.  Along with his role at TLI, Dr. Yeaman is Professor of Medicine at UCLA, and Chief, Division of Molecular Medicine at Harbor-UCLA Medical Center.    

Pathogens

Credit: The Lundquist Institute

The Lundquist Institute (TLI) at Harbor-UCLA Medical Center announced today that TLI Principal Investigator, Michael Yeaman, PhD, has been awarded a grant totaling $11.5M from the National Institute of Allergy and Infectious Diseases (NIAID), Department of Health & Human Services.  Along with his role at TLI, Dr. Yeaman is Professor of Medicine at UCLA, and Chief, Division of Molecular Medicine at Harbor-UCLA Medical Center.    

This new NIH U19 Center program will decode patterns of the human immune system and microbial pathogens that result in infections that are not cleared by antibiotics.  In turn, defining such patterns will enable new ways to predict individuals at risk of such persistent infections, and inform best antibiotic regimens for cures.  The focus of this U19 is on infections caused by the bacterium Staphylococcus, including methicillin-resistant S. aureus (MRSA) and the invasive fungus, Candida.  These pathogens are among highest priorities for public health as determined by the NIAID and Centers for Disease Control & Prevention (CDC). 

Dr. Yeaman and team made previous discoveries that laid essential groundwork for this project to find new ways to prevent and treat persistent bloodstream infections.  The new research will take an even more innovative approach to this goal.  Traditional genetics focus on the sequence of DNA to identify potential correlates of infection and immunity.  The new U19 award goes further—by exploring patterns in how DNA is modified beyond sequence in ways that impact immune response and antibiotic efficacy against infection.  This exciting frontier of biomedical research is called epigenomics. 

Working with Dr. Yeaman will be TLI Investigator Dr. Scott Filler, expert colleagues from the Immunogenetics Center and Department of Bioengineering at UCLA as well as Duke University Medical Center, plus TLI Co-Investigators Dr. Liana Chan and Dr. Marc Swidergall.  They will apply powerful immunology and computational methods to detect hidden epigenomic patterns within vast datasets.  The ultimate goal of this effort is to accelerate discovery and development of new anti-infective agents, immunotherapies, and vaccines to improve and save lives.

“We will use state-of-the-art technologies in synergistic research to understand human-pathogen interactions driving persistence,” said Dr. Yeaman. “The challenge of infections that are resistant to conventional antibiotics is growing every day—and will pose an increasing threat to public health unless we find new, improved ways to predict, prevent and cure these infections.”

The research of Dr. Yeaman and colleagues at TLI continues to be a beacon of innovation.  This new U19 award builds upon his recent $10M NIH U01 grant, which assembled a world-class team of experts to support conceptually new research in epigenomics of MRSA bloodstream infections.  This new grant adds to Dr. Yeaman’s exceptional track record as the Principal Investigator of research projects totaling over $30M in the past 7 years—each of which advances fundamentally new strategies to prevent and treat infections.  His new U19 is the only funded NIH Systems Biology Center focused on infections caused by MRSA and Candida.

“This groundbreaking research underscores the commitment of The Lundquist Institute and Harbor-UCLA to address critical public health challenges that are particularly relevant to the local community and beyond,” said David Meyer, PhD, TLI President & CEO. “The awarding of this grant is more than an institutional triumph; it is a beacon of hope for those battling antibiotic resistant infections, paving the way for potential life–saving treatments.  In alignment with the priorities of the National Institutes of Health and Centers for Disease Control & Prevention, Dr. Yeaman’s research promises not only to advance scientific understanding but also to translate those findings into tangible improvements in healthcare.”



Share12Tweet8Share2ShareShareShare2

Related Posts

Early Hyperglycemia Linked to Risks in Low Birth Weight Infants

August 29, 2025

NEXN Prevents Vascular Calcification via SERCA2 SUMOylation

August 29, 2025

Predictive Models Shape Transplant Eligibility Decisions

August 29, 2025

Enhanced Visualization of Microcystic Macular Edema in OCT

August 29, 2025

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    151 shares
    Share 60 Tweet 38
  • Molecules in Focus: Capturing the Timeless Dance of Particles

    142 shares
    Share 57 Tweet 36
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    116 shares
    Share 46 Tweet 29
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    82 shares
    Share 33 Tweet 21

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Early Hyperglycemia Linked to Risks in Low Birth Weight Infants

Isolating a Robust Heat-Resistant Metalloprotease from Geobacillus

NEXN Prevents Vascular Calcification via SERCA2 SUMOylation

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.